Sartorius Stedim Biotech and GE Healthcare sign Cross-Licensing Agreement
Agreement covers intellectual property relating to biopharmaceutical manufacturing technologies
Aubagne, France; Goettingen, Germany and Chalfont St. Giles, UK – September 12, 2011 – Sartorius Stedim Biotech has entered into a patent cross-licensing agreement with GE Healthcare Life Sciences. This will enable the further development of each company’s current and future biopharmaceutical manufacturing technologies.
“Signing this agreement represents our mutual respect for intellectual property. In the immediate term it will enable us to employ the technologies covered by the patents in the license agreements to further advance the controls of single use devices,” said Catarina Flyborg, General Manager BioProcess Products at GE Healthcare Life Sciences. “Furthermore our customers will profit from the freedom to employ these proprietary control mechanisms, without violating patent rights, when sourced from either GE Healthcare or Sartorius Stedim Biotech.”
Reinhard Vogt, Executive Vice President of Marketing, Sales and Services, Sartorius Stedim Biotech commented: “Like GE Healthcare Life Sciences, we have primarily entered into these license agreements for the benefit of our customers. The agreement will enable both our companies to provide a greater selection of products as well as accelerate the development of new and innovative technologies for applications in the biopharmaceutical manufacturing industry.”
Under the agreement, Sartorius Stedim Biotech has granted GE Healthcare Life Sciences a sublicense to certain patents held by the University of Maryland (UMBC) to which Sartorius Stedim Biotech has access under an exclusive license agreement with Fluorometrix, a spin-off of UMBC. These patent rights cover bioreactors with at least two optical sensors for monitoring biotechnological manufacturing processes. GE Healthcare Life Sciences has granted Sartorius Stedim Biotech a sublicense to patent rights that it has access to under an agreement with SciLog Inc. (www.scilog.com), a leading innovator in automated and single-use purification systems as well as disposable sensor technology. These patent rights cover proprietary technologies for the automated, aseptic transfer of solutions in bioprocessing applications. The financial terms of the agreement were not disclosed.
About GE Healthcare:
GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Our broad expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, drug discovery, biopharmaceutical manufacturing technologies, performance improvement and performance solutions services help our customers to deliver better care to more people around the world at a lower cost. In addition, we partner with healthcare leaders, striving to leverage the global policy change necessary to implement a successful shift to sustainable healthcare systems.
Our “healthymagination” vision for the future invites the world to join us on our journey as we continuously develop innovations focused on reducing costs, increasing access and improving quality around the world. Headquartered in the United Kingdom, GE Healthcare is a unit of General Electric Company (NYSE: GE). Worldwide, GE Healthcare employees are committed to serving healthcare professionals and their patients in more than 100 countries. For more information about GE Healthcare, visit our website at www.gehealthcare.com. For our latest news, please visit newsroom.gehealthcare.com
Contacts College Hill Dr Lynne Trowbridge, Tim Watson T: +44 (0)20 7866 7861 E: email@example.com